Perceived Risk of Severe Respiratory Syncytial Virus Disease and Immunoprophylaxis Use among US Pediatric Specialists

Deborah M. Friedman, Joseph B. Domachowske, Pierre C. Wong, Prabhu Parimi, Daniel F. Garcia, Michael G. Marcus, William V. La Via, Iqra A. Syed, Shelagh M. Szabo, Kimmie K. McLaurin, Veena R. Kumar

Research output: Contribution to journalArticle

Abstract

This study was conducted to assess the perception of US pediatric specialists of respiratory syncytial virus (RSV) disease risk and determine their clinical practices regarding immunoprophylaxis for high-risk children. Separate surveys were sent to neonatologists, pediatricians, pediatric pulmonologists, and pediatric cardiologists. Data were collected using structured questions requiring quantitative responses. Most neonatologists and pediatricians (>82.7%) reported a high clinical need for RSV immunoprophylaxis in preterm infants

Original languageEnglish (US)
Pages (from-to)724-737
Number of pages14
JournalClinical Pediatrics
Volume55
Issue number8
DOIs
Publication statusPublished - Jul 1 2016
Externally publishedYes

    Fingerprint

Keywords

  • cardiologist
  • neonatologist
  • palivizumab
  • pediatrician
  • pulmonologist
  • RSV

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this